FDA Approves Regeneron and Ipsen's Breakthrough Treatments for Rare Diseases
TL;DR
The FDA has approved Regeneron's monoclonal antibody, Veopoz (pozelimab), as the first treatment for Chaple disease, a rare hereditary immune disease affecting fewer than 100 people worldwide. The drug is expected to be available to patients this quarter and can be used to treat both adults and children aged one and older, who may experience severe gastrointestinal issues or blood clots due to the condition.
- FDA approves Regeneron's antibody for rare immune disease, resolves manufacturing issues for aflibercept Endpoints News
- FDA approves palovarotene capsules to treat fibrodysplasia ossificans progressiva Contemporary Pediatrics
- US FDA approves Regeneron's ultra-rare blood disease drug Reuters.com
- After much trial and error, Ipsen scores FDA nod for Sohonos FiercePharma
- FDA Approves Ipsen’s Palovarotene for Ultra-Rare Bone Disease BioSpace
- View Full Coverage on Google News
Want the full story? Read the original reporting
Read on Endpoints News